UAS Technikum Wien, Vienna, Austria.
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.
J Alzheimers Dis. 2020;75(4):1073-1082. doi: 10.3233/JAD-191210.
One of the challenges in translating new therapeutic approaches to the patient bedside lies in bridging the gap between scientists who are conducting basic laboratory research and medical practitioners who are not exposed to highly specialized journals. This review covers the literature on photobiomodulation therapy as a novel approach to prevent and treat Alzheimer's disease, aiming to bridge that gap by gathering together the terms and technical specifications into a single concise suggestion for a treatment protocol. In light of the predicted doubling in the number of people affected by dementia and Alzheimer's disease within the next 30 years, a treatment option which has already shown promising results in cell culture studies and animal models, and whose safety has already been proven in humans, must not be left in the dark. This review covers the mechanistic action of photobiomodulation therapy against Alzheimer's disease at a cellular level. Safe and effective doses have been found in animal models, and the first human case studies have provided reasons to undertake large-scale clinical trials. A brief discussion of the minimally effective and maximum tolerated dose concludes this review, and provides the basis for a successful translation from bench to bedside.
将新的治疗方法转化到患者床边的一个挑战在于弥合从事基础实验室研究的科学家与未接触过高深专业期刊的医疗从业者之间的差距。本篇综述涵盖了光生物调节疗法作为预防和治疗阿尔茨海默病的一种新方法的文献，旨在通过将术语和技术规格汇集到一个单一的治疗方案建议中来弥合这一差距。鉴于未来 30 年内受痴呆症和阿尔茨海默病影响的人数预计将翻一番，对于一种已经在细胞培养研究和动物模型中显示出有前景的结果、且其安全性已在人类中得到证实的治疗选择，绝不能置之不理。本篇综述涵盖了光生物调节疗法在细胞水平上对阿尔茨海默病的作用机制。在动物模型中已经找到了安全有效的剂量，并且首例人体病例研究为进行大规模临床试验提供了理由。简短讨论了最小有效和最大耐受剂量，为本篇综述画上句号，并为从实验室到病床的成功转化提供了基础。
